Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 555 Lymphoma 447 Precursor Cell Lymphoblastic Leukemia-Lymphoma 413 Lymphoma, Large B-Cell, Diffuse 348 Leukemia 346 Multiple Myeloma 336 Lymphoma, Non-Hodgkin 317 Leukemia, Myeloid, Acute 289 Leukemia, Lymphocytic, Chronic, B-Cell 286 Lymphoma, Follicular 241 Burkitt Lymphoma 217 Myelodysplastic Syndromes 211 Lymphoma, Mantle-Cell 202 Hodgkin Disease 193 Recurrence 155 Lymphoma, B-Cell, Marginal Zone 142 Melanoma 136 Lymphoma, Large-Cell, Immunoblastic 116 Neoplasms 109 Lymphoma, B-Cell 103 Neuroblastoma 101 Neoplasms, Plasma Cell 99 Ovarian Neoplasms 96 Triple Negative Breast Neoplasms 94 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 91 Myeloproliferative Disorders 87 Hematologic Neoplasms 87 Leukemia, Myeloid, Chronic-Phase 83 Leukemia, Myeloid, Accelerated Phase 80 Leukemia, Myelomonocytic, Chronic 78

Interventions

pertuzumab 1 azeliragon 1 Trastuzumab 1 Docetaxel 1 Cyclophosphamide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Cancer Related Cognitive Decline × Cyclophosphamide × Clear all

NCT05256745 2025-12-24

RAGE

Georgetown University

Phase 1/2 Recruiting

Cancer Related Cognitive Decline

Data powered by HemOnc (CC BY 4.0) Colophon ⚡